Intra-Cellular Therapies Aktie
119,00
EUR
-2,00
EUR
-1,65
%
127,35
USD
+0,27
USD
+0,21
%
Werbung
Intra-Cellular Therapies Aktie Analyse
08.02.18 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
15.12.17 | Intra-Cellular Therapies Buy | Canaccord Adams | |
16.12.16 | Intra-Cellular Therapies Overweight | Cantor Fitzgerald | |
29.09.16 | Intra-Cellular Therapies Neutral | SunTrust | |
29.09.16 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
17.09.15 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
14.04.15 | Intra-Cellular Therapies Outperform | RBC Capital Markets |
Werbung
Werbung